Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 2029-2037
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2029
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2029
Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma
Kai Dai, Yin Wu, Sha She, Qian Zhang, Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China
Author contributions: Dai K performed the majority of the writing and prepared the table; Wu Y, She S and Zhang Q carried out the literature review for data collection, and coordinated the writing of the paper; all authors have read and approve the final manuscript.
Supported by The National Natural Science Foundation of China , No. 81972673 .
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kai Dai, MD, PhD, Doctor, Department of Infectious Diseases, Renmin Hospital of Wuhan University, No. 238 Jiefang Road, Wuchang District, Wuhan 430060, Hubei Province, China. daikai@whu.edu.cn
Received: February 20, 2021
Peer-review started: February 20, 2021
First decision: July 29, 2021
Revised: August 4, 2021
Accepted: October 27, 2021
Article in press: October 27, 2021
Published online: December 15, 2021
Processing time: 297 Days and 10.2 Hours
Peer-review started: February 20, 2021
First decision: July 29, 2021
Revised: August 4, 2021
Accepted: October 27, 2021
Article in press: October 27, 2021
Published online: December 15, 2021
Processing time: 297 Days and 10.2 Hours
Core Tip
Core Tip: Chimeric antigen receptors (CARs)-based immunotherapy is an emerging therapeutic strategy for tumors. This review summarizes the recent advances in genetic engineering of CAR-natural killer (NK) cells against hepatocellular carcinoma and discuss the current challenges and prospects of CAR-NK cells as a revolutionary cellular immunotherapy against hepatocellular carcinoma.